{"id":1506,"date":"2026-06-17T11:34:42","date_gmt":"2026-06-17T09:34:42","guid":{"rendered":"https:\/\/ajlaw.pl\/?p=1506"},"modified":"2026-06-17T11:52:06","modified_gmt":"2026-06-17T09:52:06","slug":"attorney-at-law-joanna-uchanska-in-the-latest-issue-of-swiat-przemyslu-farmaceutycznego","status":"publish","type":"post","link":"https:\/\/ajlaw.pl\/en\/attorney-at-law-joanna-uchanska-in-the-latest-issue-of-swiat-przemyslu-farmaceutycznego\/","title":{"rendered":"Attorney-at-law Joanna Ucha\u0144ska in the latest issue of \u015awiat Przemys\u0142u Farmaceutycznego"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">In the latest issue of \u201c\u015awiat Przemys\u0142u Farmaceutycznego,\u201d an article by attorney-at-law Joanna Ucha\u0144ska, partner at AJ LAW Ucha\u0144ska Diskau, entitled \u201cRap, Prescriptions and Legal Provisions: Can Literary Interpretation Defend Itself Before the Chief Pharmaceutical Inspector and What Does It Have to Do with Pharmaceutical Advertising?\u201d has been published. The article is devoted to one of the most widely discussed decisions of the Chief Pharmaceutical Inspector in recent months and its potential consequences for the pharmaceutical market and contemporary marketing communication.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The case concerns a decision issued by the Chief Pharmaceutical Inspector on April 2, 2026, in which the authority concluded that the work of one of Poland\u2019s most popular rappers \u2013 Taco Hemingway \u2013 may exceed the limits of artistic freedom and constitute unlawful advertising of a medicinal product containing codeine. This precedent-setting decision opens a debate not only on the boundaries of pharmaceutical law, but also on the methods of interpreting cultural and artistic messages by public administration authorities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The article addresses, among others, the following issues:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 The limits of artistic freedom in light of pharmaceutical law regulations<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 An analysis of the Chief Pharmaceutical Inspector\u2019s decision of April 2, 2026, and its reasoning<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 The definition of medicinal product advertising and its practical interpretation<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 Legal risks associated with non-standard forms of communication<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 The impact of the decision on marketing and educational campaigns in the pharmaceutical industry<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 Challenges related to the interpretation of messages based on emotions, narrative, and artistic creativity<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 The future of digital communication in the context of dynamically evolving forms of expression<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2022 The significance of the decision for businesses operating in the pharmaceutical market<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We invite you to read the article!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For more information, please contact Attorney-at-law Joanna Ucha\u0144ska at: <a href=\"mailto:juchanska@ajlaw.pl\">juchanska@ajlaw.pl<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the latest issue of \u201c\u015awiat Przemys\u0142u Farmaceutycznego,\u201d an article by attorney-at-law Joanna Ucha\u0144ska, partner at AJ LAW Ucha\u0144ska Diskau, entitled \u201cRap, Prescriptions and Legal Provisions: Can Literary Interpretation Defend Itself Before the Chief Pharmaceutical Inspector and What Does It Have to Do with Pharmaceutical Advertising?\u201d has been published. The article is devoted to one of the most widely discussed decisions of the Chief Pharmaceutical Inspector in recent months and its potential consequences for the pharmaceutical market and contemporary marketing communication.<\/p>\n","protected":false},"author":5,"featured_media":1478,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[77],"tags":[332,216,258,357],"class_list":["post-1506","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","tag-article","tag-law","tag-news","tag-pharmaceutical-law"],"acf":[],"_links":{"self":[{"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/posts\/1506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/comments?post=1506"}],"version-history":[{"count":1,"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/posts\/1506\/revisions"}],"predecessor-version":[{"id":1507,"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/posts\/1506\/revisions\/1507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/media\/1478"}],"wp:attachment":[{"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/media?parent=1506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/categories?post=1506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ajlaw.pl\/en\/wp-json\/wp\/v2\/tags?post=1506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}